Pegcetacoplan is a complement inhibitor made of two identical 15-amino-acid peptides joined by a long polyethylene glycol (PEG) chain. It blocks complement protein C3, an early step in an immune cascade. This guide covers its structure, mechanism, FDA-labeled uses, pivotal trials and label warnings. Sources were checked on November 17, 2026.
Quick answer: Pegcetacoplan is a prescription C3 inhibitor sold as two products. The Empaveli label covers paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. The Syfovre label covers geographic atrophy from age-related macular degeneration. Empaveli carries a boxed warning for serious infections caused by encapsulated bacteria.
Vitrapep does not sell pegcetacoplan; this page is a reference summary of published research and regulatory information.
What is pegcetacoplan?
The Empaveli label describes “two identical pentadecapeptides covalently bound to the ends of a linear 40-kiloDalton (kDa) PEG molecule” (Empaveli label, 2026). A pentadecapeptide is a chain of 15 amino acids. PEG is a synthetic polymer, not a peptide.
So the drug counts as a peptide conjugate: the parts that bind the target are peptides, and the PEG chain adds bulk. The label gives the formula as C1970H3848N50O947S4 and the molecular weight as about 43.5 kDa. PubChem returned no compound record for the name, so these figures come from the label. Our peptide primer and peptide vs protein explainer cover the basics.
Drugs@FDA lists the original approval of Empaveli (NDA 215014) on May 14, 2021, to Apellis Pharmaceuticals (Drugs@FDA). Syfovre (NDA 217171) followed on February 17, 2023 (Drugs@FDA).
Pegcetacoplan: key facts
| Fact | Detail |
|---|---|
| Structure type | Two identical 15-amino-acid peptides joined to a linear 40 kDa PEG chain |
| Class | Complement C3 inhibitor |
| Molecular formula | C1970H3848N50O947S4 (per the Empaveli label) |
| Molecular weight | About 43.5 kDa |
| First FDA approval | May 14, 2021 (Empaveli, NDA 215014) |
| Brand names (US) | Empaveli, Syfovre |
How does pegcetacoplan work?
Complement is a set of blood proteins that tag and destroy microbes and damaged cells. C3 sits at the center of that cascade. The Empaveli label states that “pegcetacoplan binds to complement protein C3 and its activation fragment C3b.” Acting this early, it controls two routes of red cell destruction in PNH.
The first is C3b tagging, which leads to clearance of red cells outside blood vessels. The second is the membrane attack complex, which bursts red cells inside blood vessels. The PEGASUS authors note that C5 inhibition “cannot address extravascular hemolysis.” The Syfovre label describes the same C3 and C3b binding (Syfovre label, 2025). For a peptide that acts at C5 instead, see zilucoplan.
What is pegcetacoplan approved for?
The two labels list these indications:
- Empaveli (2021), PNH: “the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).”
- Empaveli, kidney disease: adults and children 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and loss of kidney function.
- Syfovre (2023): “the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).”
PNH is a rare blood disorder in which complement destroys red cells. C3G and IC-MPGN are rare kidney diseases driven by complement. Geographic atrophy is a late form of AMD in which retinal cells waste away.
What did the key trials show?
PNH (PEGASUS). This open-label, randomized phase 3 human trial enrolled 80 adults still anemic on eculizumab. It assigned 41 to pegcetacoplan and 39 to eculizumab. The primary end point was the change in hemoglobin at week 16. The adjusted mean difference was 3.84 g/dL in favor of pegcetacoplan (P<0.001) (Hillmen et al., 2021; NCT03500549).
C3G and IC-MPGN (VALIANT). The Empaveli label describes a randomized, double-blind, placebo-controlled trial in 124 patients aged 12 and older (NCT05067127). At week 26, pegcetacoplan produced a 68% greater reduction than placebo in urine protein-to-creatinine ratio (p<0.0001).
Geographic atrophy (OAKS and DERBY). Two double-masked, sham-controlled phase 3 trials randomized 1,258 patients. At month 12, OAKS met its primary end point, with 21% and 16% slower lesion growth in its two treatment arms. DERBY did not, with 12% and 11% slower growth that was not statistically significant (Heier et al., 2023). At 24 months, the Syfovre label reports lesion growth reductions of about 17% to 22% versus sham across the arms.
What side effects does the label list?
The Empaveli label has a boxed warning. It states that the drug “increases the risk of serious infections, especially those caused by encapsulated bacteria.” It adds that these infections “may become rapidly life-threatening or fatal if not recognized and treated early.” Empaveli is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).
In PNH, Empaveli reactions in 10% or more include local site reactions, infections, diarrhea and abdominal pain. Respiratory infection, limb pain, low potassium and fatigue are also listed. In C3G or IC-MPGN, it lists local site reactions, fever, nasopharyngitis, influenza, cough and nausea. Its warnings also cover monitoring of PNH after stopping and interference with some laboratory tests.
The Syfovre label has no boxed warning. Its warnings cover endophthalmitis (a serious eye infection) and retinal detachment. They also cover retinal vasculitis or vascular occlusion, neovascular AMD, eye inflammation and raised eye pressure. Its most common reactions (5% or more) include eye discomfort and neovascular AMD.
What is pegcetacoplan’s regulatory status, and how is it used in research?
Pegcetacoplan is a prescription drug in the United States. Both products are made by Apellis Pharmaceuticals. Empaveli is distributed only under a REMS because of its infection risk. The current Empaveli label was revised in August 2026, and the Syfovre label in July 2025.
The research summarized here is clinical: randomized human trials in PNH, complement-driven kidney disease and geographic atrophy. We found no documented role for pegcetacoplan as a laboratory reagent in the sources we checked.
Frequently asked questions about pegcetacoplan
Is pegcetacoplan a peptide?
It is a peptide conjugate. Two identical 15-amino-acid peptides do the binding, and a 40 kDa PEG chain links them.
When was pegcetacoplan first approved?
Drugs@FDA lists the original approval of Empaveli on May 14, 2021.
What is the difference between Empaveli and Syfovre?
Both contain pegcetacoplan. Empaveli is labeled for PNH and two complement-driven kidney diseases. Syfovre is labeled for geographic atrophy from AMD.
How is pegcetacoplan different from eculizumab?
Pegcetacoplan blocks C3, early in the complement cascade. The PEGASUS authors note that C5 inhibition cannot address extravascular hemolysis. In that trial, pegcetacoplan raised hemoglobin more than eculizumab.
Does pegcetacoplan have a boxed warning?
Empaveli does, for serious infections caused by encapsulated bacteria. Syfovre does not.
What to know now
- Structure: two 15-amino-acid peptides on a 40 kDa PEG chain; about 43.5 kDa.
- Approval: Empaveli, May 14, 2021; Syfovre, February 17, 2023; prescription only.
- Mechanism: binds complement C3 and C3b, acting early in the cascade.
- Evidence: 3.84 g/dL hemoglobin gain over eculizumab in PNH; 68% greater proteinuria reduction in C3G and IC-MPGN.
- Label: PNH, C3G and primary IC-MPGN (Empaveli); geographic atrophy (Syfovre).
- Safety: Empaveli boxed warning for encapsulated-bacteria infections, with a REMS.
What we’re watching
Further revisions to the Empaveli label on DailyMed, last revised in August 2026, and the Syfovre label. Related guides: zilucoplan, ecallantide and cyclosporine.